BioVie Inc. Banner Image

BioVie Inc. has reached its limit for free report views

Work for BioVie Inc.? Upgrade Your Profile and unlock all your annual reports.

BioVie Inc.

  • Ticker BIVI
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
BioVie Inc. Logo Image
  • 1-10 Employees
  • Based in Carson City, Nevada
BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s). It is being investigated as a potential new therapy for patients suffering from ascites, and future development opportunitiesMore include hepatorenal syndrome (HRS) and other life-threatening complications of advanced liver cirrhosis. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The Company has completed a Phase 2 clinical trial protocol that is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. BIV201 has also received Orphan Drug designation for the treatment of hepatorenal syndrome (HRS) and has FDA Fast Track status.
BioVie Inc.

Most Recent Annual Report

BioVie Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. BioVie Inc. has reached its limit for free report views.

Older/Archived Annual Reports